GHIT Fund investment
partners - Japanese and Dutch
Schistosomiasis remains a major neglected tropical disease impacting the health of the lowest income populations. To guide control programs and to enable post-elimination surveillance, there is a critical need for novel sensitive, affordable and user-friendly diagnostics.
DTECT-Schisto, which stands for Diagnostic Tools for Elimination and Control programs Targeting Schistosomiasis, kicked off in April 2018. In the first two years, the team will select and validate specific parasitic antigens (protein or glycan) for assessment of schistosome-directed antibodies in patient blood or urine. Next, the team aims to develop rapid point-of-care diagnostic test(s) for schistosomiasis, in minimally-invasive body fluids. The test should be affordable, sensitive/specific, user-friendly, rapid/robust, equipment-free, and deliverable (ASSURED).
Supporting scientific excellence
Lygature has helped to set up the consortium and acts as the Coordinator in this Dutch-Japanese partnership. We provide a range of support, thereby allowing the researchers to focus entirely on the science. Lygature’s activities include:
- Coordination and governance. As consortium coordinator, Lygature provides necessary governance in terms of monitoring progress, legal support, finance, and collaborations.
- Communication. Lygature pro-actively coordinates engagement with key stakeholders to share the consortium’s ambition of developing a simple antibody test for detecting schistosomiasis.
DTECT-Schisto is an example of the Lygature mission to bring together partners from all over the world, thereby making a meaningful contribution to tropical medicine.
Lygature together with
GHIT Fund announces investment in schistosomiasis
GHIT is investing approximately 76 million yen (US$0.7 million) in DTECT-Schisto to develop a fast, simple, antibody test capable of diagnosing schistosomiasis for control and elimination programs.